nifedipine has been researched along with Essential Hypertension in 12 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Essential Hypertension: Hypertension that occurs without known cause, or preexisting renal disease. Associated polymorphisms for a number of genes have been identified, including AGT, GNB3, and ECE1. OMIM: 145500
| Excerpt | Relevance | Reference |
|---|---|---|
| " We planned to research the effect of vitamin D and nifedipine in the treatment of patients with essential hypertension." | 9.19 | Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: a randomized placebo-controlled trial. ( Chen, WR; Chen, YD; Liu, ZY; Sha, Y; Shi, Y; Wang, H; Yin, DW, 2014) |
| "To measure the plasma concentrations of adrenomedullin (ADM),atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP), and investigate their pathophysiological functions in patients with primary aldosteronism (PA)." | 7.81 | Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism. ( Hu, W; Wang, W; Xu, CG; Zhang, XB; Zhou, PH, 2015) |
| "Meanwhile, the left ventricular remodeling, 24-hours levels of urinary microalbumin, endothelial dysfunction, and arterial stiffness were all significantly improved compared with that of the baseline and the nifedipine group (all P < ." | 6.90 | Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension. ( Chen, SB; Dong, Y; Li, YM; Liu, JX; Shi, R; Yang, GH; Zhang, JQ; Zhou, X, 2019) |
| " The primary assessment included the incidence of treatment-emergent adverse events (TEAEs)." | 6.82 | Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study. ( Dzongowski, P; Kjeldsen, SE; Li, N; Radlmaier, A; Wang, L, 2016) |
| " CR nifedipine (80 mg per day) was generally well tolerated, with the most common drug-related treatment-emergent adverse event being tachycardia (6." | 6.80 | Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension. ( Asano, K; Kajikawa, M; Kimoto, M; Matsuda, Y; Shimamoto, K, 2015) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 6.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Doxazosin mesylate GITS had similar therapeutic effects on BP, BP SD, and BP CV lowering as nifedipine GITS in patients with mild-to-moderate essential hypertension." | 5.30 | Effects of doxazosin mesylate versus nifedipine on blood pressure variability in hypertensive patients: a randomized crossover study (SIMILAR). ( Cang, H; Gong, Y; He, M; Li, Y; Liang, D; Liu, G; Pan, Y; Shi, J; Wang, W; Zhang, H; Zhang, S, 2019) |
| " We planned to research the effect of vitamin D and nifedipine in the treatment of patients with essential hypertension." | 5.19 | Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: a randomized placebo-controlled trial. ( Chen, WR; Chen, YD; Liu, ZY; Sha, Y; Shi, Y; Wang, H; Yin, DW, 2014) |
| "To measure the plasma concentrations of adrenomedullin (ADM),atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP), and investigate their pathophysiological functions in patients with primary aldosteronism (PA)." | 3.81 | Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism. ( Hu, W; Wang, W; Xu, CG; Zhang, XB; Zhou, PH, 2015) |
| " In the first study, we investigated the effects of a 3-month treatment with an ARB with additional PPARγ agonist activity, telmisartan, or with a dihydropyridine calcium channel blocker, nifedipine, on insulin signalling in patients with mild-moderate essential hypertension." | 3.80 | Effect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: a pilot study. ( Agabiti Rosei, E; De Ciuceis, C; Di Gregorio, J; Donini, C; Flati, V; La Boria, E; Pasini, E; Petroboni, B; Porteri, E; Rizzoni, D; Rossini, C; Rufo, A, 2014) |
| "Meanwhile, the left ventricular remodeling, 24-hours levels of urinary microalbumin, endothelial dysfunction, and arterial stiffness were all significantly improved compared with that of the baseline and the nifedipine group (all P < ." | 2.90 | Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension. ( Chen, SB; Dong, Y; Li, YM; Liu, JX; Shi, R; Yang, GH; Zhang, JQ; Zhou, X, 2019) |
| "Based on the western medication, to evaluate the advantages in the morning blood pressure treated with acupuncture at Fengchi (GB 20) and Neck-Jiaji (EX-B 2) combined with acupuncture technique for activating blood circulation, eliminating wind and regulating the liver and spleen in the patients with essential hypertension." | 2.87 | [Acupuncture combined with medication for morning blood pressure of essential hypertension]. ( Du, Y; Zhang, Y, 2018) |
| " The primary assessment included the incidence of treatment-emergent adverse events (TEAEs)." | 2.82 | Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study. ( Dzongowski, P; Kjeldsen, SE; Li, N; Radlmaier, A; Wang, L, 2016) |
| " CR nifedipine (80 mg per day) was generally well tolerated, with the most common drug-related treatment-emergent adverse event being tachycardia (6." | 2.80 | Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension. ( Asano, K; Kajikawa, M; Kimoto, M; Matsuda, Y; Shimamoto, K, 2015) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 2.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Essential hypertension is a complex clinical condition, characterized by multiple and concomitant abnormal activation of different regulatory and contra-regulatory pathophysiological mechanisms, leading to sustained increase of blood pressure (BP) levels." | 2.58 | How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension. ( Acone, B; Calcullo, C; Crippa, M; De Luca, N; Desideri, G; Gaudio, GV; Lonati, LM; Orselli, L; Roca, E; Scuteri, A; Tocci, G; Vulpis, V; Zaninelli, A, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tocci, G | 1 |
| Desideri, G | 1 |
| Roca, E | 1 |
| Calcullo, C | 1 |
| Crippa, M | 1 |
| De Luca, N | 1 |
| Gaudio, GV | 1 |
| Lonati, LM | 1 |
| Orselli, L | 1 |
| Scuteri, A | 1 |
| Vulpis, V | 1 |
| Acone, B | 1 |
| Zaninelli, A | 1 |
| Zhang, Y | 1 |
| Du, Y | 1 |
| Zhang, JQ | 1 |
| Yang, GH | 1 |
| Zhou, X | 1 |
| Liu, JX | 1 |
| Shi, R | 1 |
| Dong, Y | 1 |
| Chen, SB | 1 |
| Li, YM | 1 |
| Shi, J | 1 |
| Liang, D | 1 |
| Pan, Y | 1 |
| Zhang, S | 1 |
| He, M | 1 |
| Zhang, H | 1 |
| Liu, G | 1 |
| Gong, Y | 1 |
| Wang, W | 2 |
| Cang, H | 1 |
| Li, Y | 1 |
| Shimamoto, K | 2 |
| Hasebe, N | 1 |
| Ito, S | 1 |
| Kario, K | 1 |
| Kimura, K | 1 |
| Dohi, Y | 1 |
| Kawano, Y | 1 |
| Rakugi, H | 1 |
| Horiuchi, M | 1 |
| Imaizumi, T | 1 |
| Ohya, Y | 1 |
| Fang, H | 1 |
| Chen, W | 1 |
| Liu, X | 1 |
| Xu, W | 1 |
| De Ciuceis, C | 1 |
| Flati, V | 1 |
| Rossini, C | 1 |
| Rufo, A | 1 |
| Porteri, E | 1 |
| Di Gregorio, J | 1 |
| Petroboni, B | 1 |
| La Boria, E | 1 |
| Donini, C | 1 |
| Pasini, E | 1 |
| Agabiti Rosei, E | 1 |
| Rizzoni, D | 1 |
| Chen, WR | 1 |
| Liu, ZY | 1 |
| Shi, Y | 1 |
| Yin, DW | 1 |
| Wang, H | 1 |
| Sha, Y | 1 |
| Chen, YD | 1 |
| Hu, W | 1 |
| Zhou, PH | 1 |
| Zhang, XB | 1 |
| Xu, CG | 1 |
| Kimoto, M | 1 |
| Matsuda, Y | 1 |
| Asano, K | 1 |
| Kajikawa, M | 1 |
| Kato, T | 1 |
| Takiuchi, H | 1 |
| Yamaguchi, M | 1 |
| Naito, T | 1 |
| Kjeldsen, SE | 1 |
| Dzongowski, P | 1 |
| Li, N | 1 |
| Wang, L | 1 |
| Radlmaier, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-blind, Parallel-group Comparative Study Between Oral BAYA1040_CR 80 mg and 40 mg for 8 Weeks in Patients With Essential Hypertension for Whom Oral BAYA1040_CR 40 mg is Insufficient[NCT01287260] | Phase 3 | 352 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nifedipine and Essential Hypertension
| Article | Year |
|---|---|
How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Essential Hyper | 2018 |
8 trials available for nifedipine and Essential Hypertension
| Article | Year |
|---|---|
[Acupuncture combined with medication for morning blood pressure of essential hypertension].
Topics: Acupuncture Points; Acupuncture Therapy; Blood Pressure; Combined Modality Therapy; Essential Hypert | 2018 |
Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Endothelium, V | 2019 |
Effects of doxazosin mesylate versus nifedipine on blood pressure variability in hypertensive patients: a randomized crossover study (SIMILAR).
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2019 |
Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparation | 2014 |
The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Anti | 2014 |
Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: a randomized placebo-controlled trial.
Topics: Aged; Blood Pressure; C-Reactive Protein; China; Dietary Supplements; Double-Blind Method; Essential | 2014 |
Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension.
Topics: Aged; Asian People; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparations; Double-Bl | 2015 |
Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Drug Therapy, Com | 2016 |
3 other studies available for nifedipine and Essential Hypertension
| Article | Year |
|---|---|
Effect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: a pilot study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Bloc | 2014 |
Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism.
Topics: Adrenalectomy; Adrenomedullin; Adult; Atrial Natriuretic Factor; Essential Hypertension; Female; Hum | 2015 |
Ca-channel blocker-induced gingival overgrowth that improved with non-surgical therapy during visiting care: a case report.
Topics: Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Debridement; Essential Hyperte | 2015 |